These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31573798)

  • 1. Quantifying Intranasally Administered Deferoxamine in Rat Brain Tissue with Mass Spectrometry.
    Kosyakovsky J; Witthuhn BA; Svitak AL; Frey WH; Hanson LR; Fine JM
    ACS Chem Neurosci; 2019 Nov; 10(11):4571-4578. PubMed ID: 31573798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.
    Farr AC; Xiong MP
    Mol Pharm; 2021 Feb; 18(2):593-609. PubMed ID: 32926630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke.
    Hanson LR; Roeytenberg A; Martinez PM; Coppes VG; Sweet DC; Rao RJ; Marti DL; Hoekman JD; Matthews RB; Frey WH; Panter SS
    J Pharmacol Exp Ther; 2009 Sep; 330(3):679-86. PubMed ID: 19509317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease.
    Fine JM; Forsberg AC; Stroebel BM; Faltesek KA; Verden DR; Hamel KA; Raney EB; Crow JM; Haase LR; Knutzen KE; Kaczmarczek KD; Frey WH; Hanson LR
    J Neurol Sci; 2017 Sep; 380():164-171. PubMed ID: 28870559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal deferoxamine can improve memory in healthy C57 mice, suggesting a partially non-disease-specific pathway of functional neurologic improvement.
    Fine JM; Kosyakovsky J; Baillargeon AM; Tokarev JV; Cooner JM; Svitak AL; Faltesek KA; Frey WH; Hanson LR
    Brain Behav; 2020 Mar; 10(3):e01536. PubMed ID: 31960628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low percentage of aluminoxamine and ferrioxamine in uremic serum after desferrioxamine administration.
    Menéndez-Fraga P; Fernández-Martín JL; Blanco-González E; Cannata-Andía JB
    Clin Chem; 1998 Jun; 44(6 Pt 1):1262-8. PubMed ID: 9625051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
    Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
    Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thermo-sensitive keratin hydrogel against iron-induced brain injury after experimental intracerebral hemorrhage.
    Zhu Q; Gong Y; Guo T; Deng J; Ji J; Wang B; Hao S
    Int J Pharm; 2019 Jul; 566():342-351. PubMed ID: 31158456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson׳s disease.
    Fine JM; Forsberg AC; Renner DB; Faltesek KA; Mohan KG; Wong JC; Arneson LC; Crow JM; Frey WH; Hanson LR
    Brain Res; 2014 Jul; 1574():96-104. PubMed ID: 24928620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gram-positive siderophore-shuttle with iron-exchange from Fe-siderophore to apo-siderophore by Bacillus cereus YxeB.
    Fukushima T; Allred BE; Sia AK; Nichiporuk R; Andersen UN; Raymond KN
    Proc Natl Acad Sci U S A; 2013 Aug; 110(34):13821-6. PubMed ID: 23924612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Brain Delivery of Rabies Virus Glycoprotein 29-Modified Deferoxamine-Loaded Nanoparticles Reverses Functional Deficits in Parkinsonian Mice.
    You L; Wang J; Liu T; Zhang Y; Han X; Wang T; Guo S; Dong T; Xu J; Anderson GJ; Liu Q; Chang YZ; Lou X; Nie G
    ACS Nano; 2018 May; 12(5):4123-4139. PubMed ID: 29617109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solid microparticles based on chitosan or methyl-β-cyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate.
    Rassu G; Soddu E; Cossu M; Brundu A; Cerri G; Marchetti N; Ferraro L; Regan RF; Giunchedi P; Gavini E; Dalpiaz A
    J Control Release; 2015 Mar; 201():68-77. PubMed ID: 25620068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice.
    Fine JM; Baillargeon AM; Renner DB; Hoerster NS; Tokarev J; Colton S; Pelleg A; Andrews A; Sparley KA; Krogh KM; Frey WH; Hanson LR
    Exp Brain Res; 2012 Jun; 219(3):381-90. PubMed ID: 22547371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease.
    Guo C; Wang T; Zheng W; Shan ZY; Teng WP; Wang ZY
    Neurobiol Aging; 2013 Feb; 34(2):562-75. PubMed ID: 22717236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods.
    Yeatts SD; Palesch YY; Moy CS; Selim M
    Neurocrit Care; 2013 Oct; 19(2):257-66. PubMed ID: 23943316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of deferoxamine on ferric chloride-induced epilepsy in rats.
    Zou X; Jiang S; Wu Z; Shi Y; Cai S; Zhu R; Chen L
    Brain Res; 2017 Mar; 1658():25-30. PubMed ID: 28063856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An expedient reverse-phase high-performance chromatography (RP-HPLC) based method for high-throughput analysis of deferoxamine and ferrioxamine in urine.
    Arshad B; Iqbal T; Akram S; Mushtaq M
    Biomed Chromatogr; 2017 Feb; 31(2):. PubMed ID: 27503066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular Disease.
    Kosyakovsky J; Fine JM; Frey WH; Hanson LR
    Pharmaceuticals (Basel); 2021 Jan; 14(2):. PubMed ID: 33513737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect measurement of desferrioxamine and its chelated compounds aluminoxamine and ferrioxamine by Zeeman atomic absorption spectrometry.
    D'Haese PC; Lamberts LV; De Broe ME
    Clin Chem; 1989 May; 35(5):884-7. PubMed ID: 2720988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of hydroxyethyl starch conjugated deferoxamine on myocardial functional recovery following coronary occlusion and reperfusion in dogs.
    Maruyama M; Pieper GM; Kalyanaraman B; Hallaway PE; Hedlund BE; Gross GJ
    J Cardiovasc Pharmacol; 1991 Jan; 17(1):166-75. PubMed ID: 1708051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.